Complement activation assessed by C3d deposition in serum samples from healthy donors and patients with myasthenia gravis before and after efgartigimod therapy. C3d deposition was measured by flow cytometry and is expressed as fold change in median fluorescence intensity (FI) relative to healthy donor controls.
Figure 2c from Veronica et al. (2026). Originally published in Neurology: Neuroimmunology & Neuroinflammation, DOI: DOI not found. Reproduced under CC BY 4.0.
Post-treatment C3d deposition in patients with myasthenia gravis stratified by disease severity based on Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scores.
Figure 3d from Veronica et al. (2026). Originally published in Neurology: Neuroimmunology & Neuroinflammation, DOI: DOI not found. Reproduced under CC BY 4.0.
Correlation between post-treatment C3d deposition and Quantitative Myasthenia Gravis (QMG) score in patients with myasthenia gravis following efgartigimod therapy.
Figure 4c from Veronica et al. (2026). Originally published in Neurology: Neuroimmunology & Neuroinflammation, DOI: DOI not found. Reproduced under CC BY 4.0.
Publishing research using Goat Anti-Mouse IgG H&L Antibody (Cyanine 5), Cross-Adsorbed (A301660)? Please let us know so that we can list the citation on this page.
